BR100 Decreased By (-0.9%)
BR30 Decreased By (-1.15%)
KSE100 Decreased By (-0.79%)
KSE30 Decreased By (-0.9%)
AGHA 7.70 Decreased By ▼ -0.11 (-1.41%)
BECO 5.17 Decreased By ▼ -0.04 (-0.77%)
BML 57.01 Decreased By ▼ -0.49 (-0.85%)
BOP 33.90 Decreased By ▼ -0.13 (-0.38%)
CNERGY 9.98 Increased By ▲ 0.02 (0.2%)
CSIL 5.30 Decreased By ▼ -0.01 (-0.19%)
FCCL 53.15 Decreased By ▼ -1.55 (-2.83%)
FFL 16.55 Decreased By ▼ -0.14 (-0.84%)
FNEL 1.22 Decreased By ▼ -0.01 (-0.81%)
KEL 7.29 Decreased By ▼ -0.11 (-1.49%)
KOSM 5.80 Increased By ▲ 0.03 (0.52%)
LOTCHEM 29.12 Decreased By ▼ -0.20 (-0.68%)
MLCF 92.28 Decreased By ▼ -2.08 (-2.2%)
NBP 201.70 Decreased By ▼ -1.35 (-0.66%)
NCPL 56.80 Decreased By ▼ -0.20 (-0.35%)
NPL 66.99 Decreased By ▼ -0.71 (-1.05%)
OGDC 314.03 Decreased By ▼ -1.81 (-0.57%)
PACE 10.53 Decreased By ▼ -0.11 (-1.03%)
PAEL 42.00 Decreased By ▼ -1.20 (-2.78%)
PIBTL 16.54 Decreased By ▼ -0.20 (-1.19%)
PPL 215.91 Decreased By ▼ -3.87 (-1.76%)
PRL 51.15 Increased By ▲ 1.96 (3.98%)
PTC 69.87 Decreased By ▼ -0.66 (-0.94%)
SSGC 27.00 Decreased By ▼ -1.25 (-4.42%)
TBL 9.74 Decreased By ▼ -0.12 (-1.22%)
TELE 8.62 Decreased By ▼ -0.17 (-1.93%)
TPL 18.46 Increased By ▲ 0.22 (1.21%)
TPLP 13.60 Increased By ▲ 0.33 (2.49%)
TREET 22.41 Decreased By ▼ -0.31 (-1.36%)
TRG 59.30 Decreased By ▼ -0.84 (-1.4%)
World

German experts recommend AstraZeneca vaccine only for over 60s

*"After several consultations, STIKO, with the help of external experts, decided by a majority to recommend the AstraZeneca COVID-19 vaccine only for persons aged 60 years and older on the basis of available data on the occurrence of rare but very severe thromboembolic side effects," it said.
Published Updated
By

BERLIN: Germany's vaccine committee, known as STIKO, on Tuesday recommended using AstraZeneca's COVID-19 vaccine only for people aged 60 and over.

"After several consultations, STIKO, with the help of external experts, decided by a majority to recommend the AstraZeneca COVID-19 vaccine only for persons aged 60 years and older on the basis of available data on the occurrence of rare but very severe thromboembolic side effects," it said.

"Regarding the question of administering the second vaccine dose to younger persons who have already received a first dose of the AstraZeneca COVID-19 vaccine, STIKO will issue a supplementary recommendation by the end of April," it added in a statement.

Comments

Comments are closed for this article.